MK0476 Study in Adult Patients With Allergic Rhinitis
Information source: Merck
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Rhinitis Allergic
Intervention: MK0476, montelukast sodium / Duration of Treatment: 2 Weeks (Drug); Comparator: placebo / Duration of Treatment: 2 Weeks (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Merck Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck
Summary
The clinical study evaluates the efficacy and safety of MK0476 in adult patients with
allergic rhinitis.
Clinical Details
Official title: Mk0476 Phase II Dose Finding Study -Allergic Rhinitis-
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: The change from baseline in the composite nasal symptoms score (average over the 2-week treatment period) in seasonal allergic rhinitis
Eligibility
Minimum age: 15 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Adult patients with seasonal allergic rhinitis
Exclusion Criteria:
- Patients who have nasal diseases (e. g., nasal polyp, septonasal arcuation,
hypertrophic rhinitis), upper respiratory infection, sinusitis, infectious rhinitis,
ocular infection and those disease severe enough to interfere with assessment of
effectiveness
- Patients who have rhinitis medicamentosa, or nonallergic rhinitis (e. g., vasomotor
rhinitis, eosinophilia rhinitis)
- Patient has a disease of the cardiovascular, hepatic, renal, hematologic systems, or
other severe disease
Locations and Contacts
Additional Information
Starting date: February 2004
Last updated: March 9, 2007
|
